Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Stein

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
The Prostate|September 4, 2008
Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapyRobert S DiPaola, Dmitri Dvorzhinski, Anu Thalasila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology GroupRobert Gray, Judith Manola, Scott Saxman, et al.
Investigational New Drugs|November 20, 2015
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) studyManish K Thakur, Lance K Heilbrun, Shijie Sheng, et al.
Plos One|August 1, 2012
Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibitionKevin Bray, Robin Mathew, Alexandria Lau, et al.
Journal of Clinical Immunology|March 7, 2012
Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiencyRichard L Wasserman, Joseph A Church, Mark Stein, et al.
Clinical Child Psychology and Psychiatry|December 20, 2021
Home direct-to-consumer telehealth solutions for children with mental health disorders and the impact of Covid-19Sierra Norman, Shireen Atabaki, Kathleen Atmore, et al.
The Oncologist|April 20, 2016
Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate CancerNeeraj Agarwal, Jean-Pascal Machiels, Cristina Suárez, et al.
JCI Insight|August 24, 2018
Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinomaAnshuman Panda, Aguirre A de Cubas, Mark Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2019
Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell CarcinomaNaomi B Haas, Leonard J Appleman, Mark Stein, et al.
JCO Precision Oncology|September 25, 2018
Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing DataHossein Khiabanian, Kim M Hirshfield, Mendel Goldfinger, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
The Prostate|September 4, 2008
Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapyRobert S DiPaola, Dmitri Dvorzhinski, Anu Thalasila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology GroupRobert Gray, Judith Manola, Scott Saxman, et al.
Investigational New Drugs|November 20, 2015
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) studyManish K Thakur, Lance K Heilbrun, Shijie Sheng, et al.
Plos One|August 1, 2012
Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibitionKevin Bray, Robin Mathew, Alexandria Lau, et al.
Journal of Clinical Immunology|March 7, 2012
Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiencyRichard L Wasserman, Joseph A Church, Mark Stein, et al.
Clinical Child Psychology and Psychiatry|December 20, 2021
Home direct-to-consumer telehealth solutions for children with mental health disorders and the impact of Covid-19Sierra Norman, Shireen Atabaki, Kathleen Atmore, et al.
The Oncologist|April 20, 2016
Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate CancerNeeraj Agarwal, Jean-Pascal Machiels, Cristina Suárez, et al.
JCI Insight|August 24, 2018
Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinomaAnshuman Panda, Aguirre A de Cubas, Mark Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2019
Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell CarcinomaNaomi B Haas, Leonard J Appleman, Mark Stein, et al.
JCO Precision Oncology|September 25, 2018
Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing DataHossein Khiabanian, Kim M Hirshfield, Mendel Goldfinger, et al.
Pageof 7